UA82489C2 - ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ВКЛЮЧАЄ інгібітор абсорбції холестерину, інгібітор HMG-COA-редуктази ТА стабілізуючий агент, (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ - Google Patents

ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ВКЛЮЧАЄ інгібітор абсорбції холестерину, інгібітор HMG-COA-редуктази ТА стабілізуючий агент, (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ Download PDF

Info

Publication number: UA82489C2
Authority: UA; Ukraine
Prior art keywords: composition; simvastatin; composition according; ezetimibe; propyl gallate
Prior art date: 2002-07-26

Application number

UAA200501756A

Other languages

English (en)

Russian (ru)

Ukrainian (uk)

Inventor

Уилльям Д. Мур

Шон Фитцпатрик

Кристиан Зайлер

Роберт Саклатвала

Кетрин Р. Петтс

Original Assignee

Мерк Шарп Энд Доме Лимитед

Шеринг Корпорейшн

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-26

Filing date

2003-07-22

Publication date

2008-04-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA82489(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-07-22 Application filed by Мерк Шарп Энд Доме Лимитед, Шеринг Корпорейшн filed Critical Мерк Шарп Энд Доме Лимитед

2008-04-25 Publication of UA82489C2 publication Critical patent/UA82489C2/uk

Links

239000000203 mixture Substances 0.000 title claims abstract description 113
238000011282 treatment Methods 0.000 title claims description 14
238000000034 method Methods 0.000 title claims description 13
229940122502 Cholesterol absorption inhibitor Drugs 0.000 title abstract description 11
229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract description 4
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 2
239000003381 stabilizer Substances 0.000 title description 12
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 54
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 28
235000010323 ascorbic acid Nutrition 0.000 claims abstract description 27
239000011668 ascorbic acid Substances 0.000 claims abstract description 27
229960005070 ascorbic acid Drugs 0.000 claims abstract description 27
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 20
239000008101 lactose Substances 0.000 claims abstract description 20
229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 18
239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 18
229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 18
235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 18
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
235000019359 magnesium stearate Nutrition 0.000 claims abstract description 14
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 12
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 12
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 12
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 12
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 5
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 57
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 48
229960002855 simvastatin Drugs 0.000 claims description 48
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 48
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 44
229960000815 ezetimibe Drugs 0.000 claims description 35
OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 35
229920002785 Croscarmellose sodium Polymers 0.000 claims description 22
239000000473 propyl gallate Substances 0.000 claims description 22
235000010388 propyl gallate Nutrition 0.000 claims description 22
229940075579 propyl gallate Drugs 0.000 claims description 22
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 21
229960001681 croscarmellose sodium Drugs 0.000 claims description 21
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 21
235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 12
239000004255 Butylated hydroxyanisole Substances 0.000 claims description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
229920000881 Modified starch Polymers 0.000 claims description 10
201000010099 disease Diseases 0.000 claims description 8
238000009501 film coating Methods 0.000 claims description 6
239000007888 film coating Substances 0.000 claims description 6
230000002792 vascular Effects 0.000 claims description 4
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 3
229940043253 butylated hydroxyanisole Drugs 0.000 claims description 3
LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 claims 1
239000008203 oral pharmaceutical composition Substances 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
239000003963 antioxidant agent Substances 0.000 abstract description 4
235000006708 antioxidants Nutrition 0.000 abstract description 3
239000002552 dosage form Substances 0.000 description 36
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 25
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
229960001375 lactose Drugs 0.000 description 14
239000013543 active substance Substances 0.000 description 11
235000012000 cholesterol Nutrition 0.000 description 11
235000015165 citric acid Nutrition 0.000 description 11
229960004106 citric acid Drugs 0.000 description 11
229940123934 Reductase inhibitor Drugs 0.000 description 10
238000005469 granulation Methods 0.000 description 10
230000003179 granulation Effects 0.000 description 10
239000003814 drug Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
230000003143 atherosclerotic effect Effects 0.000 description 8
239000003112 inhibitor Substances 0.000 description 8
230000009467 reduction Effects 0.000 description 8
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
229940069328 povidone Drugs 0.000 description 6
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
108090000854 Oxidoreductases Proteins 0.000 description 5
102000004316 Oxidoreductases Human genes 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
208000029078 coronary artery disease Diseases 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000008187 granular material Substances 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
230000002265 prevention Effects 0.000 description 5
229940124597 therapeutic agent Drugs 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
PNAMDJVUJCJOIX-IUNFJCKHSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate;(3r,4s)-1-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1.N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 PNAMDJVUJCJOIX-IUNFJCKHSA-N 0.000 description 4
150000001840 cholesterol esters Chemical class 0.000 description 4
238000000576 coating method Methods 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000001035 drying Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
238000002156 mixing Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
229940074790 simvastatin and ezetimibe Drugs 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
-1 fibrates Chemical compound 0.000 description 3
235000014655 lactic acid Nutrition 0.000 description 3
239000004310 lactic acid Substances 0.000 description 3
229960004844 lovastatin Drugs 0.000 description 3
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
239000001630 malic acid Substances 0.000 description 3
235000011090 malic acid Nutrition 0.000 description 3
229960003512 nicotinic acid Drugs 0.000 description 3
235000001968 nicotinic acid Nutrition 0.000 description 3
239000011664 nicotinic acid Substances 0.000 description 3
239000006186 oral dosage form Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
229960002965 pravastatin Drugs 0.000 description 3
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 3
230000008569 process Effects 0.000 description 3
239000011975 tartaric acid Substances 0.000 description 3
235000002906 tartaric acid Nutrition 0.000 description 3
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
229930182558 Sterol Natural products 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
239000003613 bile acid Substances 0.000 description 2
235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
238000002845 discoloration Methods 0.000 description 2
230000029142 excretion Effects 0.000 description 2
229940125753 fibrate Drugs 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000031891 intestinal absorption Effects 0.000 description 2
238000004859 neutralization-reionization mass spectrometry Methods 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229960003912 probucol Drugs 0.000 description 2
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 2
239000012453 solvate Substances 0.000 description 2
150000003432 sterols Chemical class 0.000 description 2
235000003702 sterols Nutrition 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
JBIJLHTVPXGSAM-UHFFFAOYSA-N 2-naphthylamine Chemical compound C1=CC=CC2=CC(N)=CC=C21 JBIJLHTVPXGSAM-UHFFFAOYSA-N 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
229920002911 Colestipol Polymers 0.000 description 1
102000015779 HDL Lipoproteins Human genes 0.000 description 1
108010010234 HDL Lipoproteins Proteins 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
102000007330 LDL Lipoproteins Human genes 0.000 description 1
108010007622 LDL Lipoproteins Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108091007187 Reductases Proteins 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
NTOZOESJXIBDLD-UHFFFAOYSA-L [Ca+2].[O-]S(=O)S([O-])(=O)=O Chemical compound [Ca+2].[O-]S(=O)S([O-])(=O)=O NTOZOESJXIBDLD-UHFFFAOYSA-L 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
239000003529 anticholesteremic agent Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
229960005370 atorvastatin Drugs 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000013590 bulk material Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000007213 cerebrovascular event Effects 0.000 description 1
229960005110 cerivastatin Drugs 0.000 description 1
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001906 cholesterol absorption Effects 0.000 description 1
GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
229960002604 colestipol Drugs 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
229960005168 croscarmellose Drugs 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
238000011161 development Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000012467 final product Substances 0.000 description 1
229960003765 fluvastatin Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
230000005484 gravity Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000005461 lubrication Methods 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
239000002547 new drug Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229960002797 pitavastatin Drugs 0.000 description 1
VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
229960000672 rosuvastatin Drugs 0.000 description 1
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
235000021003 saturated fats Nutrition 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
235000010378 sodium ascorbate Nutrition 0.000 description 1
PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
229960005055 sodium ascorbate Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyrane Compounds (AREA)

UAA200501756A 2002-07-26 2003-07-22 ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ВКЛЮЧАЄ інгібітор абсорбції холестерину, інгібітор HMG-COA-редуктази ТА стабілізуючий агент, (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ UA82489C2 (uk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US39869102P	2002-07-26	2002-07-26
PCT/US2003/022889 WO2004010993A1 (en)	2002-07-26	2003-07-22	Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent

Publications (1)

Publication Number	Publication Date
UA82489C2 true UA82489C2 (uk)	2008-04-25

Family

ID=31188454

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200501756A UA82489C2 (uk)	2002-07-26	2003-07-22	ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ВКЛЮЧАЄ інгібітор абсорбції холестерину, інгібітор HMG-COA-редуктази ТА стабілізуючий агент, (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ

Country Status (38)

Country	Link
US (4)	US7229982B2 (es)
EP (2)	EP1992343A1 (es)
JP (2)	JP2005538104A (es)
KR (2)	KR20050045993A (es)
CN (2)	CN1310643C (es)
AR (2)	AR040588A1 (es)
AT (1)	ATE393628T1 (es)
AU (2)	AU2003261217B2 (es)
BR (1)	BR0312933A (es)
CA (1)	CA2493076A1 (es)
CR (1)	CR9767A (es)
DE (1)	DE60320652T2 (es)
DK (1)	DK1531805T3 (es)
EA (1)	EA008888B1 (es)
EC (2)	ECSP055573A (es)
ES (1)	ES2303603T3 (es)
GE (1)	GEP20084443B (es)
GT (2)	GT200300149A (es)
HR (2)	HRP20050081A2 (es)
IL (2)	IL166279A0 (es)
IS (1)	IS7637A (es)
MA (1)	MA27289A1 (es)
ME (3)	MEP4708A (es)
MX (1)	MXPA05001004A (es)
MY (1)	MY148689A (es)
NO (2)	NO20051033L (es)
NZ (1)	NZ537611A (es)
PA (1)	PA8577901A1 (es)
PE (1)	PE20050128A1 (es)
PL (1)	PL375065A1 (es)
PT (1)	PT1531805E (es)
RS (2)	RS50419B (es)
SI (1)	SI1531805T1 (es)
TN (1)	TNSN05022A1 (es)
TW (2)	TW200906388A (es)
UA (1)	UA82489C2 (es)
WO (1)	WO2004010993A1 (es)
ZA (1)	ZA200500196B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0215579D0 (en)	2002-07-05	2002-08-14	Astrazeneca Ab	Chemical compounds
AR040588A1 (es) *	2002-07-26	2005-04-13	Schering Corp	Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US7320972B2 (en) *	2003-11-10	2008-01-22	Microbia, Inc.	4-Biarylyl-1-phenylazetidin-2-ones
US7871998B2 (en)	2003-12-23	2011-01-18	Astrazeneca Ab	Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
KR100598326B1 (ko) *	2004-04-10	2006-07-10	한미약품 주식회사	ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
US20060046996A1 (en) *	2004-08-31	2006-03-02	Kowa Co., Ltd.	Method for treating hyperlipidemia
SA06270191B1 (ar)	2005-06-22	2010-03-29	استرازينيكا ايه بي	مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
EP1741427A1 (en) *	2005-07-06	2007-01-10	KRKA, D.D., Novo Mesto	Pharmaceutical composition comprising simvastatin and ezetimibe
US20070202159A1 (en) *	2006-02-02	2007-08-30	Mathur Rajeev S	Pharmaceutical composition comprising stabilized statin particles
BRPI0708556A2 (pt) *	2006-03-06	2011-05-31	Teva Pharma	composição de ezetimiba
AR060623A1 (es)	2006-04-27	2008-07-02	Astrazeneca Ab	Compuestos derivados de 2-azetidinona y un metodo de preparacion
KR20140079441A (ko)	2006-06-19	2014-06-26	알파마 파머슈티컬스 엘엘씨	약제학적 조성물
CN1994296B (zh) *	2006-08-02	2010-06-16	浙江京新药业股份有限公司	一种含有辛伐他汀的药物制剂
GB0713707D0 (en)	2007-07-13	2007-08-22	Generics Uk Ltd	Stable compositions
AU2008281640A1 (en) *	2007-07-27	2009-02-05	Cipla Limited	Pharmaceutical compositions and process for making them
WO2009024889A2 (en)	2007-08-21	2009-02-26	Ranbaxy Laboratories Limited	Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
EA017941B1 (ru) *	2007-12-17	2013-04-30	Крка, Товарна Здравил, Д.Д., Ново Место	Суспензия, содержащая микрочастицы эзетимиба
US20090233898A1 (en) *	2008-03-11	2009-09-17	Glenmark Generics Ltd	Pharmaceutical Compositions Comprising Simvastatin and Ezetimibe
TR200806302A2 (tr) *	2008-08-22	2010-03-22	Bi̇lgi̇ç Mahmut	Çözünürlük ve stabilite artırıcı farmasötik formülasyon.
EP2168573A1 (en) *	2008-09-30	2010-03-31	LEK Pharmaceuticals D.D.	Formulations comprising ezetimibe
MX344885B (es) *	2008-11-10	2017-01-10	Psicofarma S A De C V	Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
EP2204170A1 (en) *	2008-12-01	2010-07-07	LEK Pharmaceuticals D.D.	Pharmaceutical composition comprising ezetimibe and simvastatin
WO2010066687A2 (en) *	2008-12-11	2010-06-17	Dsm Ip Assets B.V.	Stabalized statin-comprising compositions
EP2216016A1 (en)	2009-02-06	2010-08-11	LEK Pharmaceuticals d.d.	Process for the preparation of a pharmaceutical composition comprising ezetimibe
EP2448919A2 (en) *	2009-07-02	2012-05-09	Mahmut Bilgic	Solubility and stability enchancing pharmaceutical formulation
WO2011002424A2 (en)	2009-07-02	2011-01-06	Bilgic Mahmut	Solubility and stability enchancing pharmaceutical formulation
EP2448564A2 (en) *	2009-07-02	2012-05-09	Bilgic Mahmut	Solubility enhancing pharmaceutical formulation
EP2368543A1 (en)	2010-03-25	2011-09-28	KRKA, tovarna zdravil, d.d., Novo mesto	Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
KR101302243B1 (ko) *	2010-07-28	2013-09-02	씨제이제일제당 (주)	로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물
CN101978953A (zh) *	2010-10-11	2011-02-23	上海交通大学	基于易吸湿性辅料的固体制剂
EP2468258A1 (en)	2010-12-22	2012-06-27	LEK Pharmaceuticals d.d.	Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
WO2012104752A1 (en)	2011-02-02	2012-08-09	Alpharma Pharmaceuticals, Llc	Pharmaceutical composition comprising opioid agonist and sequestered antagonist
CN102266323B (zh) *	2011-08-04	2013-03-27	海南锦瑞制药股份有限公司	依折麦布和辛伐他汀组合物及其制备方法
EP2753309B1 (de)	2011-09-08	2020-01-01	Hexal AG	Pharmazeutische zusammensetzung zur oralen darreichung mit einem statin
WO2013166114A1 (en) *	2012-05-01	2013-11-07	Althera Life Sciences, Llc	Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe
PT2844233T (pt) *	2012-05-01	2020-06-25	Althera Life Sciences Llc	Formulação de comprimido oral que consiste numa combinação fixa de rosuvastatina e ezetimiba para o tratamento de hiperlipidemia e doenças cardiovasculares
RU2547574C2 (ru) *	2013-07-09	2015-04-10	Общество с ограниченной ответственностью "Трейдсервис"	Лекарственная форма гиполипидемического действия и способ ее изготовления
CN103585146B (zh) *	2013-11-09	2015-04-01	北京中申专利科技有限公司	辛伐他汀的药物组合物
TWI586380B (zh) *	2013-12-18	2017-06-11	夢製藥公司	包含ＨＭＧ－ＣｏＡ還原酶抑制劑及膽固醇吸收抑制劑之醫藥組合製劑
CN104306348B (zh) *	2014-09-30	2017-05-31	地奥集团成都药业股份有限公司	一种辛伐他汀片及其制备方法
BR112018009238A8 (pt) *	2015-11-06	2019-02-26	Gemphire Therapeutics Inc	tratamento de dislipidemia mista
CN106937952A (zh) *	2016-01-04	2017-07-11	重庆华邦制药有限公司	依折麦布和辛伐他汀的制剂
EP3281649A1 (en) *	2016-08-09	2018-02-14	Teleflex Lifesciences	Wetting agent formulation
JP6937195B2 (ja) *	2017-09-01	2021-09-22	興和株式会社	医薬組成物
WO2019101150A1 (zh) *	2017-11-23	2019-05-31	浙江海正药业股份有限公司	一种海泽麦布片剂及其制备方法
US11833133B2 (en) *	2020-08-13	2023-12-05	Orient Pharma Co., Ltd.	Solid oral pharmaceutical composition
TWI760067B (zh) *	2020-08-13	2022-04-01	友霖生技醫藥股份有限公司	固態口服醫藥組成物
CN112168801A (zh) *	2020-10-22	2021-01-05	哈药集团技术中心	一种辛伐他汀片的制备方法
CN115227659B (zh) *	2022-08-19	2023-05-02	北京百奥药业有限责任公司	一种依折麦布辛伐他汀组合物及其制备方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444784A (en) *	1980-08-05	1984-04-24	Merck & Co., Inc.	Antihypercholesterolemic compounds
US5366738A (en) *	1982-07-29	1994-11-22	Merck & Co., Inc.	Controlled release drug dispersion delivery device
EP0276807A3 (en)	1987-01-27	1988-10-12	Warner-Lambert Company	Lipid regulating compositions
US4820850A (en)	1987-07-10	1989-04-11	Merck & Co., Inc.	Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US4916239A (en)	1988-07-19	1990-04-10	Merck & Co., Inc.	Process for the lactonization of mevinic acids and analogs thereof
US4990535A (en) *	1989-05-03	1991-02-05	Schering Corporation	Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
CA2040865C (en)	1990-05-15	2002-07-23	James L. Bergey	Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5622985A (en) *	1990-06-11	1997-04-22	Bristol-Myers Squibb Company	Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
IL100091A (en) *	1990-12-12	1998-08-16	Zeneca Ltd	Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5688787A (en) *	1991-07-23	1997-11-18	Schering Corporation	Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
IL102582A0 (en)	1991-07-23	1993-01-14	Schering Corp	Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5688785A (en)	1991-07-23	1997-11-18	Schering Corporation	Substituted azetidinone compounds useful as hypocholesterolemic agents
US5162117A (en) *	1991-11-22	1992-11-10	Schering Corporation	Controlled release flutamide composition
NZ245514A (en) *	1991-12-27	1994-12-22	Merck & Co Inc	Controlled release drug delivery device comprising a core and a polymeric coating which is water impermeable but contains apertures to expose the core
LT3300B (en) *	1992-12-23	1995-06-26	Schering Corp	Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en)	1993-01-21	1995-12-27	Schering Corp	Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
JPH06247854A (ja) *	1993-02-24	1994-09-06	Ss Pharmaceut Co Ltd	アスコルビン酸含有組成物
US5631365A (en) *	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5976570A (en) *	1993-12-21	1999-11-02	Applied Analytical Industries, Inc.	Method for preparing low dose pharmaceutical products
US6369103B1 (en) *	1994-01-18	2002-04-09	Bristol-Myers Squibb Company	Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5627176A (en)	1994-03-25	1997-05-06	Schering Corporation	Substituted azetidinone compounds useful as hypocholesterolemic agents
AU2943095A (en) *	1994-06-20	1996-01-15	Schering Corporation	Substituted azetidinone compounds useful as hypocholesterolemic agents
US6268392B1 (en) *	1994-09-13	2001-07-31	G. D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US5807834A (en) *	1994-09-20	1998-09-15	Pfizer Inc.	Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US5624920A (en)	1994-11-18	1997-04-29	Schering Corporation	Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) *	1994-11-18	1997-05-27	Schering Corporation	Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en)	1994-12-21	1997-08-12	Schering Corporation	4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
KR100311554B1 (ko) *	1995-10-31	2002-06-20	둘락 노먼 씨.	콜레스테롤저하제로유용한슈가-치환된2-아제티디논
JP2000508659A (ja) *	1996-04-17	2000-07-11	メルクエンドカンパニーインコーポレーテッド	心血管疾患関連の危険性を低減する組み合わせ療法
US6673831B1 (en)	1996-04-17	2004-01-06	Merck & Co., Inc.	Combination therapy for reducing the risks associated with cardiovascular disease
WO1998001116A1 (en)	1996-07-09	1998-01-15	Merck & Co., Inc.	Therapy for combined hyperlipidemia
FR2751540B1 (fr) *	1996-07-26	1998-10-16	Sanofi Sa	Composition pharmaceutique antithrombotique
US5952003A (en) *	1996-08-01	1999-09-14	Novartis Corporation	Terazosin capsules
US6235706B1 (en) *	1996-09-18	2001-05-22	Merck & Co., Inc.	Combination therapy for reducing the risks associated with cardiovascular disease
US6251852B1 (en) *	1996-09-18	2001-06-26	Merck & Co., Inc.	Combination therapy for reducing the risks associated with cardiovascular disease
US5756470A (en)	1996-10-29	1998-05-26	Schering Corporation	Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6024981A (en)	1997-04-16	2000-02-15	Cima Labs Inc.	Rapidly dissolving robust dosage form
US6245797B1 (en) *	1997-10-22	2001-06-12	Merck & Co., Inc.	Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
FR2772615B1 (fr) *	1997-12-23	2002-06-14	Lipha	Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
AU754767B2 (en)	1998-06-24	2002-11-21	Merck & Co., Inc.	Compositions and methods for treating elevated blood cholesterol
JP2002518449A (ja)	1998-06-24	2002-06-25	メルクエンドカムパニーインコーポレーテッド	高血中コレステロールを治療する組成物および方法
US6099865A (en) *	1998-07-08	2000-08-08	Fmc Corporation	Croscarmellose taste masking
US6268352B1 (en) *	1998-09-02	2001-07-31	The Regents Of The University Of California	Promoters of neural regeneration
JP2000109882A (ja) *	1998-10-01	2000-04-18	Nof Corp	油性粉末、製造方法および用途
SA99191255B1 (ar)	1998-11-30	2006-11-25	جي دي سيرل اند كو	مركبات سيليكوكسيب celecoxib
US6207822B1 (en)	1998-12-07	2001-03-27	Schering Corporation	Process for the synthesis of azetidinones
US6569461B1 (en) *	1999-03-08	2003-05-27	Merck & Co., Inc.	Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
CA2365869A1 (en)	1999-03-08	2000-09-14	Richard D. Tillyer	Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
CA2364253A1 (en)	1999-03-08	2000-09-14	Merck & Co., Inc.	Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
ATE306263T1 (de)	1999-03-10	2005-10-15	Searle Llc	Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere
JP2000302672A (ja) *	1999-04-16	2000-10-31	Taisho Pharmaceut Co Ltd	咀嚼可能な被覆錠剤
JP3732039B2 (ja) *	1999-05-21	2006-01-05	三菱化学フーズ株式会社	錠剤用組成物
WO2001008687A1 (en)	1999-08-03	2001-02-08	Lilly Icos Llc	Beta-carboline pharmaceutical compositions
US6328995B1 (en) *	1999-09-24	2001-12-11	Basf Aktiengesellschaft	Stable vitamin and/or carotenoid products in powder form and process for their production
WO2001041770A2 (en) *	1999-12-08	2001-06-14	Pharmacia Corporation	Nanoparticulate eplerenone compositions
SK287105B6 (sk)	1999-12-20	2009-12-07	Schering Corporation	Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
US6248359B1 (en)	2000-01-05	2001-06-19	Laboratorios Phoenix U.S.A., Inc.	Multi-tablet oxybutynin system for treating incontinence
JP5140222B2 (ja)	2000-02-29	2013-02-06	ブリストル−マイヤーズスクイブカンパニー	低用量エンテカビル製剤およびその使用
WO2002020457A1 (en) *	2000-09-06	2002-03-14	Merck & Co., Inc.	Dihydroxy open-acid salt of simvastatin
PE20020718A1 (es) *	2000-12-20	2002-08-09	Schering Corp	2-azetidinonas sustituidas con azucares utiles como agentes hipocolesterolemicos
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
WO2002053573A1 (en) *	2000-12-28	2002-07-11	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxypyrazole derivatives and use thereof in medicines
IL156585A0 (en)	2001-01-26	2004-01-04	Schering Corp	Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
EP1363668B1 (en)	2001-01-26	2007-08-15	Schering Corporation	Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
ATE331512T1 (de)	2001-01-26	2006-07-15	Schering Corp	Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
JP2004517920A (ja)	2001-01-26	2004-06-17	シェーリング　コーポレイション	血管状態を治療するためのステロール吸収阻害剤と血液調整剤との組合せ
MEP27808A (en)	2001-01-26	2010-10-10	Schering Corp	Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CN1275949C (zh)	2001-03-28	2006-09-20	先灵公司	2－吖丁啶酮中间体化合物的对映体选择性合成
AR040588A1 (es) *	2002-07-26	2005-04-13	Schering Corp	Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa

2003
- 2003-07-16 AR AR20030102560A patent/AR040588A1/es unknown
- 2003-07-17 MY MYPI20032695A patent/MY148689A/en unknown
- 2003-07-21 PE PE2003000726A patent/PE20050128A1/es not_active Application Discontinuation
- 2003-07-22 PT PT03771709T patent/PT1531805E/pt unknown
- 2003-07-22 UA UAA200501756A patent/UA82489C2/uk unknown
- 2003-07-22 ME MEP-47/08A patent/MEP4708A/xx unknown
- 2003-07-22 HR HR20050081A patent/HRP20050081A2/xx not_active Application Discontinuation
- 2003-07-22 EP EP08103776A patent/EP1992343A1/en not_active Withdrawn
- 2003-07-22 WO PCT/US2003/022889 patent/WO2004010993A1/en not_active Ceased
- 2003-07-22 HR HR20080518A patent/HRP20080518A2/xx not_active Application Discontinuation
- 2003-07-22 AT AT03771709T patent/ATE393628T1/de not_active IP Right Cessation
- 2003-07-22 GE GEAP8662A patent/GEP20084443B/en unknown
- 2003-07-22 PA PA20038577901A patent/PA8577901A1/es unknown
- 2003-07-22 EP EP03771709A patent/EP1531805B1/en not_active Revoked
- 2003-07-22 GT GT200300149A patent/GT200300149A/es unknown
- 2003-07-22 RS YUP-2005/0061A patent/RS50419B/sr unknown
- 2003-07-22 CN CNB038178443A patent/CN1310643C/zh not_active Expired - Fee Related
- 2003-07-22 IL IL16627903A patent/IL166279A0/xx unknown
- 2003-07-22 EA EA200500279A patent/EA008888B1/ru not_active IP Right Cessation
- 2003-07-22 CN CNA2007100850256A patent/CN101069684A/zh active Pending
- 2003-07-22 MX MXPA05001004A patent/MXPA05001004A/es active IP Right Grant
- 2003-07-22 RS RSP-2008/0072A patent/RS20080072A/sr unknown
- 2003-07-22 BR BR0312933-0A patent/BR0312933A/pt not_active IP Right Cessation
- 2003-07-22 PL PL03375065A patent/PL375065A1/xx not_active Application Discontinuation
- 2003-07-22 DK DK03771709T patent/DK1531805T3/da active
- 2003-07-22 ME MEP-308/08A patent/MEP30808A/xx unknown
- 2003-07-22 DE DE60320652T patent/DE60320652T2/de not_active Revoked
- 2003-07-22 SI SI200331222T patent/SI1531805T1/sl unknown
- 2003-07-22 KR KR1020057001458A patent/KR20050045993A/ko not_active Ceased
- 2003-07-22 CA CA002493076A patent/CA2493076A1/en not_active Abandoned
- 2003-07-22 ME MEP-2008-308A patent/ME00207B/me unknown
- 2003-07-22 US US10/625,004 patent/US7229982B2/en not_active Expired - Fee Related
- 2003-07-22 AU AU2003261217A patent/AU2003261217B2/en not_active Ceased
- 2003-07-22 ES ES03771709T patent/ES2303603T3/es not_active Expired - Lifetime
- 2003-07-22 GT GT200300149AK patent/GT200300149AA/es unknown
- 2003-07-22 JP JP2004524692A patent/JP2005538104A/ja active Pending
- 2003-07-22 NZ NZ537611A patent/NZ537611A/en not_active IP Right Cessation
- 2003-07-22 KR KR1020087017824A patent/KR20080070089A/ko not_active Ceased
- 2003-07-25 TW TW097131985A patent/TW200906388A/zh unknown
- 2003-07-25 TW TW092120442A patent/TW200412944A/zh unknown
2005
- 2005-01-10 ZA ZA200500196A patent/ZA200500196B/en unknown
- 2005-01-10 IS IS7637A patent/IS7637A/is unknown
- 2005-01-25 EC EC2005005573A patent/ECSP055573A/es unknown
- 2005-01-26 TN TNP2005000022A patent/TNSN05022A1/en unknown
- 2005-02-11 MA MA28095A patent/MA27289A1/fr unknown
- 2005-02-25 NO NO20051033A patent/NO20051033L/no unknown
2007
- 2007-03-12 US US11/716,595 patent/US20070160666A1/en not_active Abandoned
2008
- 2008-02-26 CR CR9767A patent/CR9767A/es unknown
- 2008-02-28 EC EC20080055732008005573A patent/ECSP085573A/es unknown
- 2008-03-12 US US12/047,223 patent/US20080275020A1/en not_active Abandoned
- 2008-05-08 NO NO20082156A patent/NO20082156L/no not_active Application Discontinuation
- 2008-05-11 IL IL191348A patent/IL191348A0/en unknown
- 2008-06-09 JP JP2008150227A patent/JP2008291034A/ja not_active Withdrawn
- 2008-06-17 AR ARP080102576A patent/AR067030A2/es not_active Application Discontinuation
2009
- 2009-02-26 AU AU2009200768A patent/AU2009200768A1/en not_active Abandoned
- 2009-05-26 US US12/472,021 patent/US7718643B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
BR0312933A (pt)	2005-07-12
DE60320652T2 (de)	2009-06-10
IS7637A (is)	2005-01-10
PL375065A1 (en)	2005-11-14
AU2003261217B2 (en)	2009-06-04
NO20051033L (no)	2005-04-25
JP2005538104A (ja)	2005-12-15
WO2004010993A1 (en)	2004-02-05
IL166279A0 (en)	2006-01-15
HRP20050081A2 (en)	2005-08-31
DK1531805T3 (da)	2008-07-07
EP1531805A1 (en)	2005-05-25
CN101069684A (zh)	2007-11-14
HRP20080518A2 (hr)	2009-03-31
GT200300149AA (es)	2009-07-09
PA8577901A1 (es)	2004-10-08
SI1531805T1 (sl)	2008-08-31
TNSN05022A1 (en)	2007-05-14
US20070160666A1 (en)	2007-07-12
ES2303603T3 (es)	2008-08-16
IL191348A0 (en)	2008-11-03
AR040588A1 (es)	2005-04-13
AU2003261217A1 (en)	2004-02-16
ME00008B (me)	2010-02-10
GEP20084443B (en)	2008-08-10
US20090253675A1 (en)	2009-10-08
ECSP055573A (es)	2005-04-18
RS20080072A (sr)	2008-11-28
NO20082156L (no)	2005-04-25
KR20050045993A (ko)	2005-05-17
ECSP085573A (es)	2008-03-26
RS20050061A (sr)	2007-09-21
CN1310643C (zh)	2007-04-18
US20080275020A1 (en)	2008-11-06
TW200906388A (en)	2009-02-16
MA27289A1 (fr)	2005-04-01
US7229982B2 (en)	2007-06-12
RS50419B (sr)	2009-12-31
NZ537611A (en)	2007-04-27
ME00207B (me)	2011-02-10
KR20080070089A (ko)	2008-07-29
HK1080384A1 (en)	2006-04-28
AR067030A2 (es)	2009-09-30
EA008888B1 (ru)	2007-08-31
CN1671376A (zh)	2005-09-21
DE60320652D1 (de)	2008-06-12
GT200300149A (es)	2004-03-04
MXPA05001004A (es)	2005-05-16
TW200412944A (en)	2004-08-01
EP1992343A1 (en)	2008-11-19
EA200500279A1 (ru)	2005-06-30
MEP30808A (en)	2010-10-10
PE20050128A1 (es)	2005-03-22
US7718643B2 (en)	2010-05-18
ATE393628T1 (de)	2008-05-15
MEP4708A (xx)	2010-02-10
PT1531805E (pt)	2008-06-19
AU2009200768A1 (en)	2009-03-19
US20040126423A1 (en)	2004-07-01
CR9767A (es)	2008-04-10
JP2008291034A (ja)	2008-12-04
MY148689A (en)	2013-05-31
ZA200500196B (en)	2006-07-26
EP1531805B1 (en)	2008-04-30
CA2493076A1 (en)	2004-02-05

Publication	Publication Date	Title
UA82489C2 (uk)	2008-04-25	ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ВКЛЮЧАЄ інгібітор абсорбції холестерину, інгібітор HMG-COA-редуктази ТА стабілізуючий агент, (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ
KR100645866B1 (ko)	2006-11-15	발데콕시브 조성물
CN105120845A (zh)	2015-12-02	药物组合药物
CA2534660A1 (en)	2005-02-10	Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent
US6890941B1 (en)	2005-05-10	Compositions containing HMG Co-A reductase inhibitors and policosanol
CN101455842A (zh)	2009-06-17	HMG-CoA还原酶抑制剂和普罗布考的药物组合物
JPH09227371A (ja)	1997-09-02	粥状動脈硬化抑制剤
HK1125578A (en)	2009-08-14	Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent
HK1115059A (en)	2008-11-21	Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent
US20070160663A1 (en)	2007-07-12	Single unit pharmaceutical composition comprising a mixture of fenofibrate and a modified release form of a homocysteine reducing agent
HK1080384B (en)	2007-12-21	Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent
RU2192856C1 (ru)	2002-11-20	Гипохолестеринемическое средство